CharlieKey takeaways from your favorite podcasts
← 11 November 2026Invest Like the Best

GLP-1s Are a Bigger Business Than AI

Zach Reitano argues American healthcare fails because the patient isn't the customer, and that direct-pay models like GLP-1s, outcome-focused technology and a sharply focused company culture can fix it.

Watch on YouTube ↗

Charlie's summary

  1. Healthcare should take as much of GDP as possible; the real problem is cost per unit, not total spend

    Zach thinks healthcare is “the sinquon of life” and the one good with no diminishing returns, so spending 50 to 70% of GDP is fine if the money buys results. Under Jevons paradox, market size grows as cost per unit falls. The US reaches 18% because unit costs keep rising, and Zach sees it as a preview for other countries: the UK went from 6 to 12, Germany from 9 to 12. Judge the spend by what it delivers.

    ▶ 0:32
  2. The patient is not the customer, and that is healthcare's central flaw

    Zach says whoever controls the flow of money at the point of purchase is the customer, and in healthcare that isn't the patient. Care feels best where patients pay cash: LASIK and cosmetic surgery see costs fall while quality and convenience improve. His proposal is a healthcare-only credit card plus catastrophic insurance, so providers must earn trust and publish prices. Ro's bet is that aggregating patient spend can “bend the healthare system to the will of patients.”

    ▶ 5:02
  3. GLP-1s show direct-to-consumer works: cutting out PBMs and insurers took prices from $1,300 to $149

    Politicians chased price transparency for 20 to 25 years. Then pharma went direct and the gap between list and net price vanished. Zach calls PBMs “the appendex of the healthare system.” For cash-pay GLP-1s, prices fell from $1,300 to $149 while drugmakers earned as much or more, and Lilly's volume far outstrips the price cuts. Zach reads this as proof that removing middlemen lowers prices without hurting innovators.

    ▶ 6:04
  4. Ro wins by being a demand aggregator whose only durable edge is continued innovation

    Ro went from about a $250 million to over a $3 billion run rate in four years with fewer people than in 2021. Zach says its edge isn't one feature but constant invention: Ro built its own EMR, lab, pharmacy software and provider network before GLP-1s arrived. It integrates with both Novo and Lilly. Pharma comes to Ro because it puts what patients want first, and Zach is happy for drug inventors to earn more margin than distributors.

    ▶ 10:10

Give your email to unlock the rest of the key points — for every episode.

Do more with Charlie

Free — sign in with your email, no password.